Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of OBIZUR for perioperative hemostatic control in congenital hemophilia A with factor VIII inhibitors
2015-005521-39Phase 3Unknown
- Sponsor
- Baxalta
- Start
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of susoctocog alfa in hemophilia A, sponsored by Baxalta. Primary endpoint: Perioperative hemostatic efficacy. Status: unknown.
02
Drugs
susoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2015-005521-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005521-39.